AstraZeneca PLC EO-Medium-Term Nts 2023(23/27)
- BID
100.295
- ASK
100.433
- 550,000 Nom.550,000 Nom.
- 07/27, 16:15:36 PM
Type of financial instrument
Corporate Bond
Sub-Type
Health Care
Yield
3.10
Yield spread Bundesanleihe
0.3690
Tradable for private investors
No
Minimum amount tradeable unit
100,000.00
Maturity
03/03/2027
Interest Rate
3.625 %
Currency
Euro
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE / YIELD | 100.295 G / 3.10 | 0 Units |
| PRICE DETERMINATION TIME | 07/27/2026 / 04:03:40 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | 0.3690 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 100.311 | 99.889 |
| PREV. DAY'S PRICE | 100.323 | (07/24) |
| CHANGE DAY BEFORE | -0.03 | -0.03 % |
| 52 WEEK HIGH / LOW | 102.168 (07/28) | 99.091 (06/22) |
Master Data
| WKN | A3LEV7 |
| ISIN | XS2593105393 |
| SYMBOL | - |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Health Care |
| ISSUER | AstraZeneca PLC |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 3.625 % |
| INTEREST RUN FROM | 03/03/2023 |
| NEXT INTEREST PAYMENT | 03/03/2027 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 1.47 % |
| TRADING CURRENCY / NOTATION | Euro/ Percent |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 750.00 Mil. |
| MINIMUM AMOUNT TRADEABLE UNIT | 100,000.00 |
| SMALLEST TRADEABLE UNIT | 1,000.00 |
| MATURITY | 03/03/2027 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | Yes |
| BOND IS SUBORDINATED | No |
Description
Make Whole Call Option. Callable bond.
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.